par Fontana, Marianna;Berk, John L;Gillmore, Julian JD;Witteles, Ronald M;Grogan, Martha;Drachman, Brian;Damy, Thibaud;Garcia-Pavia, Pablo;Taubel, Jorg;Solomon, Scott D;Sheikh, Farooq FH;Tahara, Nobuhiro;González-Costello, José;Tsujita, Kenichi;Morbach, Caroline;Pozsonyi, Zoltán;Petrie, Mark C;Delgado, Diego;Van der Meer, Peter;Jabbour, Andrew;Bondue, Antoine 
;Kim, Darae;Azevedo, Olga;Hvitfeldt Poulsen, Steen;Yilmaz, Ali;Jankowska, Ewa A;Algalarrondo, Vincent;Slugg, Andrew;Garg, Pushkal P;Boyle, Katherine L;Yureneva, Elena;Silliman, Nancy;Yang, Lilli;Chen, Jihong;Eraly, Satish SA;Vest, John;Maurer, Mathew S;HELIOS-B Trial Investigators,
Référence The New England journal of medicine
Publication Publié, 2024-08-30
;Kim, Darae;Azevedo, Olga;Hvitfeldt Poulsen, Steen;Yilmaz, Ali;Jankowska, Ewa A;Algalarrondo, Vincent;Slugg, Andrew;Garg, Pushkal P;Boyle, Katherine L;Yureneva, Elena;Silliman, Nancy;Yang, Lilli;Chen, Jihong;Eraly, Satish SA;Vest, John;Maurer, Mathew S;HELIOS-B Trial Investigators, Référence The New England journal of medicine
Publication Publié, 2024-08-30
Article révisé par les pairs
| Résumé : | Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive, fatal disease. Vutrisiran, a subcutaneously administered RNA interference therapeutic agent, inhibits the production of hepatic transthyretin. |
